Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. (Q42978706)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18508296%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

title

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18508296%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

0 references

1 reference

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18508296%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Yi-Hsin Yang

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18508296%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

Ming-Lung Yu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18508296%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Chia-Yen Dai

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18508296%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Chang-Fu Chiu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18508296%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Nai-Jen Hou

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18508296%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Li-Po Lee

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18508296%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Ming-Yen Hsieh

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18508296%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Zu-Yau Lin

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18508296%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Shinn-Cherng Chen

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18508296%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Ming-Yuh Hsieh

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18508296%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Liang-Yen Wang

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18508296%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Wen-Yu Chang

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18508296%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Wan-Long Chuang

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18508296%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

language of work or name

English

0 references

publication date

1 June 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18508296%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18508296%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18508296%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18508296%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

1884-1893

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18508296%20AND%20SRC:MED&resulttype=core&format=json

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

8 January 2020

cites work

1 reference

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

21 January 2018

1 reference

21 January 2018

1 reference

7 January 2021

Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection

1 reference

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

7 January 2021

Diagnosis, management, and treatment of hepatitis C

1 reference

7 January 2021

A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan

1 reference

7 January 2021

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

1 reference

7 January 2021

Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy

1 reference

7 January 2021

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy

1 reference

7 January 2021

Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response.

1 reference

7 January 2021

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

1 reference

7 January 2021

A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C

1 reference

7 January 2021

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study

1 reference

7 January 2021

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

1 reference

7 January 2021

Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia

1 reference

7 January 2021

Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial

1 reference

7 January 2021

Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C.

1 reference

7 January 2021

Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection

1 reference

7 January 2021

Classification of chronic viral hepatitis: a need for reassessment

1 reference

7 January 2021

Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha

1 reference

7 January 2021

Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

1 reference

7 January 2021

Evaluating the cost of sustained virologic response in naïve chronic hepatitis C patients treated à la carte.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.22319

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18508296%20AND%20SRC:MED&resulttype=core&format=json

release_aswf6eit25aipnjjnzy5cp6dtm

8 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/aswf6eit25aipnjjnzy5cp6dtm

24 November 2022

mapped directly with Wikidata item

1 reference